RxDoctor Payments Data

James Hall, DO

Hematology & Oncology · San Angelo, TXNPI 1164800892

Payments from drug & device makers

$3,091in general payments, 2019–2025

Across 53 payments — averaging $58.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Seagen Inc.$578
  • Astellas Pharma US Inc$530
  • Pfizer$169
  • Rigel Pharmaceuticals, Inc.$109
  • Jazz Pharmaceuticals Inc.$109
  • plus $567 from 13 others

What the payments were for

  • Food & beverage$1,15137%
  • Education$94331%
  • Other$99732%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,091 in reported general payments places this provider in the 35th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas

Medicare billing

Part B allowed, 2024
$171,010
Medicare patients
334
Services billed
1,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TabrectaCapmatinib Hydrochloride19$435,378
JakafiRuxolitinib Phosphate14$273,554
TagrissoOsimertinib Mesylate13$219,482
KisqaliRibociclib Succinate14$197,677
IbrancePalbociclib12$188,459
Lenalidomide19$181,630
Abiraterone Acetate47$157,125
XtandiEnzalutamide11$152,573
EliquisApixaban103$74,575
XareltoRivaroxaban31$28,352
Anastrozole125$3,138
Ondansetron Hcl95$1,552
Exemestane19$1,538
Enoxaparin Sodium21$1,250
Gabapentin56$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTabrecta, Kisqali$1,029$633,05533 claims
PfizerIbrance, Eliquis$169$263,034115 claims
AstraZenecaTagrisso$39$219,48213 claims
Astellas Pharma US IncXtandi$530$152,57311 claims
Johnson & JohnsonXarelto$74$28,35231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 838 hematology & oncology providers in Texas.

Other hematology & oncology in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →